222 related articles for article (PubMed ID: 28402333)
1. MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells.
Lin YC; Chang YT; Campbell M; Lin TP; Pan CC; Lee HC; Shih JC; Chang PC
Sci Rep; 2017 Apr; 7():46338. PubMed ID: 28402333
[TBL] [Abstract][Full Text] [Related]
2. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling.
Lin TP; Chang YT; Lee SY; Campbell M; Wang TC; Shen SH; Chung HJ; Chang YH; Chiu AW; Pan CC; Lin CH; Chu CY; Kung HJ; Cheng CY; Chang PC
Oncotarget; 2016 May; 7(18):26137-51. PubMed ID: 27034167
[TBL] [Abstract][Full Text] [Related]
3. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells.
Chang PC; Wang TY; Chang YT; Chu CY; Lee CL; Hsu HW; Zhou TA; Wu Z; Kim RH; Desai SJ; Liu S; Kung HJ
PLoS One; 2014; 9(2):e88556. PubMed ID: 24551118
[TBL] [Abstract][Full Text] [Related]
4. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.
Wu JB; Shao C; Li X; Li Q; Hu P; Shi C; Li Y; Chen YT; Yin F; Liao CP; Stiles BL; Zhau HE; Shih JC; Chung LW
J Clin Invest; 2014 Jul; 124(7):2891-908. PubMed ID: 24865426
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase A drives neuroendocrine differentiation in prostate cancer.
Shui X; Ren X; Xu R; Xie Q; Hu Y; Qin J; Meng H; Zhang C; Zhao J; Shi C
Biochem Biophys Res Commun; 2022 May; 606():135-141. PubMed ID: 35349822
[TBL] [Abstract][Full Text] [Related]
6. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Weber H; Ruoff R; Garabedian MJ
PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
[TBL] [Abstract][Full Text] [Related]
7. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy.
Han H; Li H; Ma Y; Zhao Z; An Q; Zhao J; Shi C
Cancer Lett; 2023 Jun; 563():216188. PubMed ID: 37076041
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.
Xu S; Adisetiyo H; Tamura S; Grande F; Garofalo A; Roy-Burman P; Neamati N
Br J Cancer; 2015 Jul; 113(2):242-51. PubMed ID: 26103574
[TBL] [Abstract][Full Text] [Related]
10. Targeting monoamine oxidase A in advanced prostate cancer.
Flamand V; Zhao H; Peehl DM
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1761-71. PubMed ID: 20204405
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase A inhibitor-near-infrared dye conjugate reduces prostate tumor growth.
Wu JB; Lin TP; Gallagher JD; Kushal S; Chung LW; Zhau HE; Olenyuk BZ; Shih JC
J Am Chem Soc; 2015 Feb; 137(6):2366-74. PubMed ID: 25585152
[TBL] [Abstract][Full Text] [Related]
12. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.
Fujiwara J; Sowa Y; Horinaka M; Koyama M; Wakada M; Miki T; Sakai T
Int J Oncol; 2012 May; 40(5):1483-91. PubMed ID: 22328338
[TBL] [Abstract][Full Text] [Related]
13. MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.
Li J; Pu T; Yin L; Li Q; Liao CP; Wu BJ
Oncogene; 2020 Apr; 39(16):3305-3321. PubMed ID: 32066880
[TBL] [Abstract][Full Text] [Related]
14. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
Liao CP; Lin TP; Li PC; Geary LA; Chen K; Vaikari VP; Wu JB; Lin CH; Gross ME; Shih JC
Oncogene; 2018 Sep; 37(38):5175-5190. PubMed ID: 29844571
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
16. Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling.
Li J; Yang XM; Wang YH; Feng MX; Liu XJ; Zhang YL; Huang S; Wu Z; Xue F; Qin WX; Gu JR; Xia Q; Zhang ZG
J Hepatol; 2014 Jun; 60(6):1225-34. PubMed ID: 24607627
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria-targeted prostate cancer therapy using a near-infrared fluorescence dye-monoamine oxidase A inhibitor conjugate.
Lv Q; Yang X; Wang M; Yang J; Qin Z; Kan Q; Zhang H; Wang Y; Wang D; He Z
J Control Release; 2018 Jun; 279():234-242. PubMed ID: 29679664
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.
Hirano D; Okada Y; Minei S; Takimoto Y; Nemoto N
Eur Urol; 2004 May; 45(5):586-92; discussion 592. PubMed ID: 15082200
[TBL] [Abstract][Full Text] [Related]
19. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM
Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
